AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03350217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eleview
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
Study NCT03350217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hetastarch
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
Study NCT03070158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Promotion
Description: Attachment Promotion consists of:~1. Education session about newborn and mother care.~2. Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~3. Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~4. Daily Phone follows up.
Study NCT03053479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Description: see arm/group descriptions
Study NCT03053479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh procedure
Description: see arm/group descriptions
Study NCT03053479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amreich-Richter procedure
Description: see arm/group descriptions
Study NCT02918019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: MSTT1041A will be administered as subcutaneous injections.
Study NCT02918019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with MSTT1041A.
Study NCT00584480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Treatment (HBOT)
Description: 1.5 ATA at 100% Oxygen of HBOT
Study NCT01704352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia
Description: CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
Study NCT03353870 — intervention group
Intervention type: OTHER
Intervention: qualitative interview
Description: individual qualitative interview
Study NCT01019382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipidem fish oil infusion + Gemcitabine chemotherapy
Description: 500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
Study NCT03099486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
Study NCT03099486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
Study NCT03099486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
Study NCT04312490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: endomyocardial biopsy
Description: Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
Study NCT02481388 — intervention group
Intervention type: OTHER
Intervention: Maximal exercise ramp test
Description: The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
Study NCT00411554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
Study NCT00411554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: voglibose
Description: voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
Study NCT03216356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + ImRs
Description: Cognitive Behavioral Therapy with Imagery Rescripting
Study NCT03216356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + ImRs
Description: Cognitive Behavioral Therapy with Imagery Rescripting
Study NCT03216356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + I.E.
Description: Cognitive Behavioral Therapy with Imagery Exposure
Study NCT03216356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 250 mg DCS (derived from Seromycin 250 mg capsules)
Study NCT03216356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: polyethylene glycol 3350 powder
Study NCT03216356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Pill
Description: 250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
Study NCT03355508 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pucture in the arteriovenous fistula
Description: The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw.
Study NCT02870361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Study NCT02870361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03090594 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
Study NCT01891331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161
Study NCT01891331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study NCT03624322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa IM
Description: 5mg
Study NCT03624322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydis
Description: 10mg orally disintegrating wafer
Study NCT03624322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INP105
Description: Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
Study NCT03624322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I231 POD® Device
Description: Precision Olfactory Delivery (POD) device
Study NCT02171585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study NCT02171585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study NCT01081795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
Study NCT01081795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
Study NCT01081795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
Study NCT04758585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy
Description: Shoulder Arthroscopy
Study NCT03534427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump rope exercise intervention
Description: 12-week jump rope exercise program
Study NCT00505999 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire taking 30-40 minutes to complete.
Study NCT03578120 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pre-school booster vaccine
Description: Routine vaccination with pre-school booster vaccine
Study NCT05823597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar Intensive Treatment
Description: see arm description
Study NCT05823597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Control
Description: see arm description
Study NCT01365559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: Carfilzomib & Non-IMiD Regimen
Description: Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study.
Study NCT01365559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: Carfilzomib & IMiD containing regimen.
Description: Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study.
Study NCT01618214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
Study NCT01618214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
Study NCT01595776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cells intramuscular implant
Description: After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
Study NCT04455373 — intervention group
Intervention type: PROCEDURE
Intervention: pediatric vascular bypass grafting
Description: pediatric vascular bypass grafting
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi prescription
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huoxue prescription
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buyang huanwu decoction
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QISHEN YIQI DRIPPING PILLS
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
Study NCT02875639 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
Study NCT01536860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: 300 ml of liquid food product
Study NCT01536860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 300 ml of liquid food product
Study NCT03108950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement to Music
Description: The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
Study NCT00684788 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: employment-based reinforcement
Description: Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages.
Study NCT03579355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DFND Program
Description: The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
Study NCT03592095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
Study NCT03592095 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo needle
Description: Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
Study NCT03757910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
Study NCT03757910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-MK-6240
Description: This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 4
Description: Guselkumab will be administered by IV infusion.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 5
Description: Guselkumab will be by SC injection.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered by IV infusion and SC injection.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab will be administered by IV infusion and SC injection.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered by IV infusion and SC injection.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IV infusion.
Study NCT03757910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PIB
Description: This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
Study NCT03757910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-PIB
Description: This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
Study NCT00571350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tvt-o operation
Description: transvaginal tention free obturator tape
Study NCT00571350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tvt o operation
Description: transobturator vaginal tape insertion
Study NCT00944164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating and physical activity
Description: Parent counseling and coaching regarding healthy eating and physical activity habits for their child
Study NCT00944164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety and injury prevention
Description: Parent counseling and coaching regarding general personal and household safety
Study NCT02640417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotides + B12
Description: Oral treatment with either Nucleotides + Vitamin B12
Study NCT02640417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B Vitamins
Description: Oral treatment with vitamins B1, B6, and B12
Study NCT03743870 — intervention group
Intervention type: DRUG
Intervention: Levobupivacaine
Description: Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
Study NCT03743870 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
Study NCT01606111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
Study NCT01606111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl, saline
Description: IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
Study NCT02475148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/high Calorie Breakfast
Study NCT03038425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
Study NCT03038425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
Study NCT03158870 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery complications
Description: Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
Study NCT01993693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Diathermy Device
Description: The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
Study NCT01993693 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Ultrasonic Diathermy Device
Description: Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound